Clinical Trial Update: DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating DT2216 in combination with paclitaxel for platinum-resistant ovarian cancer. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• DT2216
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Elizabeth Stover, MD, PhD | Conditions: Ovarian Cancer, Ovarian Carcinoma | Phase 1 | Status: RECRUITING